Search clinical trials for: rituximab [MabThera/Rituxan]

Total 3383 results

Fred Hutchinson Cancer Center
GlaxoSmithKline

Completed

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

Uganda
The Lymphoma Academic Research Organisation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; Swiss Group... and other collaborators

Recruiting

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (MorningLyte)

Follicular Lymphoma

Belgium, France, Germany, Portugal, Spain
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission

Radiotherapy | Advanced Diffuse Large B-Cell Lymphoma | Extra-nodal Involvement, Large Mass
Celgene

Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Lymphoma, B-Cell

United States, Greece, Spain, Australia, Poland, Taiwan, Korea, Republic of
Masonic Cancer Center, University of Minnesota

Recruiting

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Severe Aplastic Anemia | Bone Marrow Failure | T Cell Receptor Alpha/Beta Depletion | Telomere Biology Disorder

United States
Fudan University

Unknown

Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

Thalidomide

China
Buddhist Tzu Chi General Hospital

Terminated

Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori

Helicobacter Pylori Infection

Taiwan
Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
University of Chicago

Recruiting

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

HPV-Negative Squamous Cell Carcinoma

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Recruiting

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

Metastatic Colorectal Cancer

United States, Belgium, China, Canada, Denmark, France, Norway, Romania, Spain, United Kingdom, Austria, Brazil, Germany, Netherlands, Argentina, Czechia, Ireland, Italy, Turkey, Chile, Greece, Puerto Rico, Australia, Japan
M.D. Anderson Cancer Center

Active, not recruiting

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Colon Cancer | Resected Stage

United States
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Radboud University Medical Center
Erasmus Medical Center; Leiden University Medical Center; Medical Center Haaglanden and other collaborators

Active, not recruiting

A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (COMMENCE)

Squamous Cell Carcinoma of the Head and Neck

Netherlands
GlaxoSmithKline

Withdrawn

Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer (ELATE)

Neoplasms, Breast

Hungary, Norway, Austria, Spain
Masonic Cancer Center, University of Minnesota

Recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Acquired Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Acquired Amegakaryocytic Thrombocytopenia

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Relapsed or Refractory Follicular Lymphoma
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico, Australia, Israel, Korea, Republic of, Romania, Serbia, Spain, Taiwan
University of Birmingham
Cancer Research UK; Genmab

Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United Kingdom
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma (ZR2-CHOP)

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

China
National Cancer Institute (NCI)

Recruiting

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Primary Central Nervous System Lymphoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Completed

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Breast Cancer

United States
Heidelberg University

Unknown

Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma (HD-MCL2003)

Mantle-Cell Lymphoma

Germany
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (POSIBA)

Colorectal Cancer

Spain
University Hospital of Crete

Terminated

Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

Colorectal Cancer

Greece
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
UNICANCER

Completed

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Colorectal Cancer

France
UNICANCER

Completed

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Colorectal Cancer

France
National Cancer Institute (NCI)

Completed

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (MAESTRO HN)

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States, China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Double Expressor Lymphoma | High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements

United States
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Diffuse Large B-Cell Lymphoma
Shandong Provincial Hospital

Recruiting

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

China
Xiqiang Dang
The First Affiliated Hospital of Anhui Medical University; LanZhou University; Guangzhou First People's Hospital and other collaborators

Recruiting

Multicenter Registry of Pediatric Lupus Nephritis in China

Children | Lupus Nephritis | Steroid | Immunosuppressive Treatment

China
Seoul National University Hospital

Recruiting

Korean College of Rheumatology Biologics and Targeted Therapy Registry (KOBIO)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Korea, Republic of
Institute of Hematology & Blood Diseases Hospital

Recruiting

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma

China
National Institute of Allergy and Infectious Diseases...
Johns Hopkins University; PPD

Active, not recruiting

COVID Protection After Transplant-Immunosuppression Reduction (CPAT-ISR)

Liver Transplant Recipients | Kidney Transplant Recipients

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
UMC Utrecht; Amsterdam University Medical Centers; The Dutch Network for Cardiovascular...

Not yet recruiting

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (HO170DLBCL)

DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
Kite, A Gilead Company

Recruiting

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)

Relapsed/Refractory Follicular Lymphoma

United States, Spain, United Kingdom, Italy, France, Japan, Germany
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Unknown

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma (DLCL04)

Diffuse Large B-Cell Lymphoma | IPI≥2

Italy
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Colorectal Neoplasms

China
Technische Universität Dresden

Unknown

Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases (CELIM2)

Colorectal Cancer

Germany
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Merck Sharp & Dohme LLC

Terminated

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Neoplasms
Eli Lilly and Company

Completed

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Colorectal Cancer | Metastatic Melanoma | Advanced Cancer | Metastatic Non-small Cell Lung Cancer

United States, Japan, Australia, France
Peking University
Zhejiang University; Liaoning Tumor Hospital & Institute

Active, not recruiting

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

mCRC

China
M.D. Anderson Cancer Center

Completed

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Advanced Cancers

United States
Timothy Voorhees

Active, not recruiting

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University Hospital Southampton NHS Foundation...
AstraZeneca

Recruiting

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A)

Diffuse Large B Cell Lymphoma

United Kingdom

Search clinical trials for: rituximab [MabThera/Rituxan]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations